Glucose is central to energy metabolism in the brain, both in astrocytes and neurons, and defects in glucose metabolic pathways have been documented in neurodegenerative disorders (Mathur, Lopez‐Rodas, Casanova, & Marti, 2014): Pyruvate levels are increased in patients with multiple sclerosis (McArdle, Mackenzie, & Webster, 1960), while impaired GAPDH and ECT components were found in both AD and HD patients (Brooks et al., 2007; Chandrasekaran et al., 1994; Mazzola & Sirover, 2001; Regenold, Phatak, Makley, Stone, & Kling, 2008). This evidence concerns the gene GAPDH and Alzheimer disease.